Oseltamivir
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Uncomplicated acute illness due to influenza A and B infection in patients > 2 weeks of age and older who have been symptomatic for no more than 2 days.
- Efficacy not established (by prospective trials) if symptom onset > 48h duration.
- Prophylaxis of influenza in ages ≥ 1 yr of age.
NON-FDA APPROVED USES
- Severe illness due to influenza A and B infection in immunocompromised and elderly pts who are hospitalized, even if > 48h symptoms--though limited data regarding efficacy 3 - 5 days post symptom onset.
- The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics recommend the use of oseltamivir for prophylaxis in infants > 3 months of age.
- COVID-19:
- Coronaviruses are not known to utilize neuraminidase in viral replication; therefore, oseltamivir is unlikely to be of any therapeutic value.
- In one series of 138 hospitalized patients with COVID-19, approximately 90% received oseltamivir, with no reported evidence of benefit.
- Coronaviruses are not known to utilize neuraminidase in viral replication; therefore, oseltamivir is unlikely to be of any therapeutic value.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Uncomplicated acute illness due to influenza A and B infection in patients > 2 weeks of age and older who have been symptomatic for no more than 2 days.
- Efficacy not established (by prospective trials) if symptom onset > 48h duration.
- Prophylaxis of influenza in ages ≥ 1 yr of age.
NON-FDA APPROVED USES
- Severe illness due to influenza A and B infection in immunocompromised and elderly pts who are hospitalized, even if > 48h symptoms--though limited data regarding efficacy 3 - 5 days post symptom onset.
- The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics recommend the use of oseltamivir for prophylaxis in infants > 3 months of age.
- COVID-19:
- Coronaviruses are not known to utilize neuraminidase in viral replication; therefore, oseltamivir is unlikely to be of any therapeutic value.
- In one series of 138 hospitalized patients with COVID-19, approximately 90% received oseltamivir, with no reported evidence of benefit.
- Coronaviruses are not known to utilize neuraminidase in viral replication; therefore, oseltamivir is unlikely to be of any therapeutic value.
There's more to see -- the rest of this entry is available only to subscribers.